A study in Labour Economics reports that drugs used to treat attention-deficit/hyperactivity disorder (ADHD) in children may reduce the likelihood of risky sexual behavior outcomes, substance abuse disorders,…
On May 30, the U.S. Food and Drug Administration (FDA) approved the first generic versions of Strattera (atomoxetine) to treat attention-deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.…
Please share your feedback! We’re interested to learn more about your experience with American Nurse Journal.
Get your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.